Dolby Laboratories, Inc.

Fundamentals7.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Low leverage
  • Strong liquidity
  • Softening margins

AI
AI Summary

6.0

Dolby's move from a predictable licensing cash generator to an execution‑dependent platform/partner growth story (Vision 2, automotive, patent pool) creates meaningful upside if commercial deals scale but materially raises short‑term revenue and cash‑flow volatility tied to partner timing. Monitor quarterly NCFO/FCF stabilization, patent‑pool monetization cadence, and sequential revenue/margin improvements as the specific go/no‑go signals before relying on buybacks/dividends or re-rating the stock.

ExecutionUpside
ExecutionRisk
BalanceSheet‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • Low leverage
  • Strong liquidity
  • Softening margins

DLB combines very low leverage and a large cash/working-capital buffer with solid historical FCF, but recent quarter weakness—softer margins, declining operating cash flow, and rising payout/expense pressure—raises near‑term risk.

cashbuffer
marginpressure

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below last month SMA
  • Oversold momentum
  • Testing nearby support

DLB is in a short-term downtrend (below its last month SMA ≈ $63.6) after a ~5.7% decline over the last month, sitting near support at $60–$61 with an oversold RSI (~25) that raises the chance of a bounce but keeps risk elevated until $65–$66 resistance is reclaimed.

bounce
downtrend
Support Level: $60–$61
Resistance Level: $65–$66

~5.7% decline over the last month with small intraperiod recoveries on 2026-03-16 and 2026-03-19

Sentiment & News

6.0

Key News Insights:

  • Industry tailwinds
  • Institutional reallocation
  • Targeted clinical progress

Dolby (DLB) sees improving industry sentiment and at least one institutional reallocation while separate DLB (dementia with Lewy bodies) clinical/regulatory advances — notably neflamapimod subgroup benefit and CT1812 regulatory planning — signal targeted therapeutic progress.

DLB

Positive consumer-demand and macro trends may support Dolby's earnings/stock outlook, while focused clinical wins and regulatory strategy de-risk select DLB therapeutic programs